Oncopharmpod
Trilaciclib, Cemiplimab & GU Updates
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:19:58
- More information
Informações:
Synopsis
Topics covered: 1. Trilaciclib's approval to minimize bone marrow suppression 2. Cemiplimab's approval for mNSLC with high PD-L1 expression 3. A brief anti-BCMA CAR-T phase II trial in multiple myeloma 4. Confirmation of enfortumab vedotin's benefit in metastatic bladder cancer 5. More of the same with lenvatinib + pembrolizumab in mRCC
